ASCO GU 2023: Talazoparib Improves Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
The PARP inhibitor appears effective regardless of homologous recombination repair status
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.